Navigation Links
Why chemotherapy causes more infertility in women than in men
Date:2/22/2011

Chemotherapeutic agents, used in cancer treatment, destroy not only cancer cells but also healthy cells, thus affecting germ cells as well. Consequently, after surviving cancer many female patients are confronted with the diagnosis: infertility. For a long time a relationship between infertility and chemotherapeutic agents has been assumed, but until now, the exact mechanism was not known.

Scientists from the research group of Prof. Volker Dtsch (Institute of Biophysical Chemistry, Goethe University Frankfurt) in cooperation with international partners have now started to unveil the mechanism of cancer treatment related infertility. Their results are published in the internationally renowned journal Cell. Mainly women suffer from infertility because the quality control in the oocytes is different from male germ cells. Male germ cells are produced throughout the whole life span but the number of female germ cells is restricted and already fixed before birth. If the oocytes are damaged during cancer treatment, they are destroyed by the female quality control mechanism.

Essential for this process is the protein p63 which shows striking similarity to another important protein of the same family: p53. p53 is also named "guardian of the genome" because of its regulatory function in cell division and cell death of damaged cells and, therefore, plays a key role in the suppression of genetic anomalies which could lead to cancer. In more than half of all human tumors p53 is altered and no longer functional.

For a long time the exact regulation of p53 and p63 and the similarities and differences between these two proteins have been the object of many international research projects. In the currently accepted model the concentration of p53 in healthy cells is relatively low. If genetic anomalies occur in a cell which could cause the transition to a cancer cell, the concentration of p53 increases and four p53 proteins form a tetramer. In this tetrameri
'/>"/>

Contact: Prof. Volker Doetsch
vdoetsch@em.uni-frankfurt.de
49-697-982-9631
Goethe University Frankfurt
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A loose grip provides better chemotherapy
2. Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy
3. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
4. Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer
5. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
6. Identifying subsets of patients who will respond to subsequent lines of chemotherapy
7. New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports
8. TGen finds protein inhibitor revives chemotherapy for ovarian patients
9. Duke develops nano-scale drug delivery for chemotherapy
10. Common chemotherapy drug triggers fatal allergic reactions
11. CSHL team develops mouse models of leukemia that predict response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... Society applauds the Government of Argentina for creating two ... with majestic shorelines and abundant wildlife. The new ... Marine Parkwere recently established by the National Congress in ... other marine and coastal species., "We commend the Government ...
... This press release is available in German . ... of human infants was investigated using the prominent ,Stanford Marshmallow Experiment,: ... could either eat it now or wait and receive a second ... delay of several minutes. Interestingly, children that were able to wait ...
... study published online today in Nature Communications , researchers ... Sciences, BGI-Shenzhen, and University of Arizona have completed the genome ... provides new insights for researchers to understand the function and ... Oryza is an idea model system for studying plant ...
Cached Biology News:2 new marine protected areas created on Argentina's southern coasts 22 new marine protected areas created on Argentina's southern coasts 3Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)... LONDON , May 21, 2015 ... your inner feelings - and those of others. Being ... and senses. Analyze and read people to anticipate their ... your deepest emotions and feelings to create unique ... generation of responsive games. Get inside a first-person-shooter as ...
(Date:5/21/2015)... , May 20, 2015 Research and Markets ... addition of the "2015 Global Survey on ... offering. The primary goal of this ... cytometry instruments and reagents. Key information the survey ... selection of flow cytometers, predominantly used applications for ...
(Date:5/20/2015)... May 20, 2015 Research and Markets ... "Top Technologies in HW_Technical Insights" report to ... report evaluated technology trends in the Health and Wellness ... likely to have an impact in the year 2015. ... the top 10 health and wellness technologies that are ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2
... Even HealthierST. LOUIS, March 31 Recent research reveals ... be beneficial to the diet. And, the majority recognizes ... such as soyfoods even healthier. These findings come from ... - sponsored by the United Soybean Board (USB) ...
... Shire plc (LSE: SHP,NASDAQ: SHPGY ), ... agreement with GlaxoSmithKline plc (NYSE: GSK ... aim of,improving recognition and treatment of ADHD in ... and will more than double the reach and,frequency ...
... U.S. FDA approves Intercell,s first marketed product, a new ... - Commercial product launch in the U.S. planned for ... today announced that the U.S. Food and Drug Administration ... of Japanese Encephalitis (JE). The initial target for use ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4